Grifols (GRFS) Depreciation & Amortization (CF) (2010 - 2020)
Grifols' (GRFS) quarterly Depreciation & Amortization (CF) came in at $85.6 million in Q1 2020, up 1.15% YoY from $84.7 million in Q2 2019, and down 65.48% on a QoQ basis from $248.1 million in Q4 2019.
Grifols (GRFS) Depreciation & Amortization (CF) (2010 - 2020) Analysis & Trends
Grifols (GRFS) has 11 years of Depreciation & Amortization (CF) data on file, last reported at $85.6 million in Q1 2020.
- Quarterly Depreciation & Amortization (CF) rose 1.15% year-over-year to $85.6 million in Q1 2020, while the trailing twelve-month figure through Dec 2021 was $85.6 million (down 74.34% YoY) and the FY2021 annual result came in at $411.6 million, up 12.11% from the prior year.
- Depreciation & Amortization (CF) fell to $85.6 million in Q1 2020, from $248.1 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.4 billion in Q2 2017 to a low of $55.6 million in Q3 2016.
- A 5-year average of $451.9 million and a median of $186.5 million in 2017 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2017 — Depreciation & Amortization (CF) slumped 95.29% — and 2019, when it jumped 30.64%.
- Tracing GRFS's Depreciation & Amortization (CF) over 5 years: stood at $1.4 billion in 2016, then tumbled by 86.64% to $186.5 million in 2017, then advanced by 1.84% to $189.9 million in 2018, then surged by 30.64% to $248.1 million in 2019, then tumbled by 65.48% to $85.6 million in 2020.
- The last three Depreciation & Amortization (CF) figures came in at $85.6 million (Q1 2020), $248.1 million (Q4 2019), and $84.7 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.96 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.11 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.62 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 85.64 Mn |
| Mar 31, 2020 | 85.64 Mn |
| Dec 31, 2019 | 248.08 Mn |
| Dec 31, 2019 | 248.08 Mn |
| Mar 31, 2019 | 84.66 Mn |
| Mar 31, 2019 | 84.66 Mn |
| Dec 31, 2018 | 189.89 Mn |
| Dec 31, 2018 | 189.89 Mn |
| Mar 31, 2018 | 64.97 Mn |
| Mar 31, 2018 | 64.97 Mn |
| Dec 31, 2017 | 186.46 Mn |
| Dec 31, 2017 | 186.46 Mn |
| Jun 30, 2017 | 1.40 Bn |
| Jun 30, 2017 | 1.40 Bn |
| Mar 31, 2017 | 56.80 Mn |
| Mar 31, 2017 | 56.80 Mn |
| Dec 31, 2016 | 1.40 Bn |
| Dec 31, 2016 | 1.40 Bn |
| Sep 30, 2016 | 55.63 Mn |
| Sep 30, 2016 | 55.63 Mn |